Upper GI

MULTI-001 Nivolumab v11

MULTI-002 Carboplatin and etoposide v1

MULTI-003 Pembrolizumab v11

MULTI-014 Irinotecan & Capecitabine v1

MULTI-018 Larotrectinib v2

MULTI-019 Entrectinib v2

MULTI-021 Carboplatin and paclitaxel v1

MULTI-026 Trifluridine & Tipiracil (Lonsurf®) v1

MULTI-027 Cabozantinib (Cabometyx®) v1

MULTI-028 Regorafenib v1
MULTI-032 OXALIPLATIN & MOD de GRAMONT v1

UGI-005 CF without radiotherapy v6

UGI-006 CX without radiotherapy v6

UGI-007 CARBO X v5

UGI-008 CarboF v6

UGI-023 Sorafenib v7

UGI-036 CARBOPLATIN and PACLITAXEL with radiotherapy v4

UGI-037 DCF v3

UGI-039 Modified Folfirinox (palliative) v5

UGI-040 Everolimus NET v4

UGI-047 Nab-Paclitaxel (Abraxane) ® Gemcitabine v6
UGI-052 CarboX & Trastuzumab IV v1

UGI-058 FLOT v3

UGI-059 Capecitabine for resected biliary tract cancer v1

UGI-060 Lenvatinib (LENVIMA®) v2

UGI-061 Folfirinox (adjuvant) v1

UGI-062 OX (reduced dose) v1

UGI-066 Atezolizumab (SC) and Bevacizumab v4

UGI-067 Pemigatinib v2

UGI-069 Pembrolizumab in combination with chemotherapy v2

UGI-070 OX (standard dose, continuous capecitabine) v1

UGI-071 CF (Chemoradiation – based on SCOPE2) v2

UGI-072 CX (Chemoradiation – based on SCOPE2) v1

UGI-073 OX (standard dose, continuous capecitabine) and trastuzumab IV v1

UGI-074 Nivolumab in combination with chemotherapy v2

UGI-075 CarboF (Chemoradiation – based on SCOPE2) v1

UGI-076 Carbo X (Chemoradiation – based on SCOPE2) v2

UGI-077 Durvalumab with Gemcitabine and cisplatin v1

UGI-078 Ivosidenib v1